One of the primary objectives of any medical imaging procedure is to provide accurate and, if possible, quantitative information to aid the diagnosis and treatment of disease. In oncology X-ray CT, Ultrasound and most recently Magnetic Resonance Imaging all provide high resolution morphological information. Conventional radioisotope imaging whilst providing unique functional information is generally limited by poor spatial resolution and sensitivity. If the development of tissue malignancy can be detected in its early stages through biochemical processes and if the effects of treatment are best seen by changes in these processes then a high resolution, quantitative, functional imaging technique is required. The only technique satisfying these criteria is Positron Emission Tomography (PET).
anti-cancer drug kinetics, receptor mechanisms and tumour targeting. In some cases the information provided by these studies is already being used directly in the clinic to provide valuable guidance in the management of cancer patients and it is likely that this will increase steadily in future.
Perfusion, metabolism and permeability measurements A wide variation in tumour perfusion has been reported by Beaney et al. (1985 Beaney et al. ( , 1987 . These data indicate that even in cases where there is a plentiful supply of blood and, hence, oxygen, the tumour often has only a modest demand for this supply. It has also been demonstrated by Patronas et al. (1982) and Brooks et al. (1986) (Knopp et al., 1990) reductions in glucose metabolism of lung tumours responding to radio-or chemotherapy. Alavi et al. (1988) have measured a strong correlation between initial glucose metabolism and prognosis for patients with primary cerebral tumours, the result appearing stronger than that predicted by a simple histological grading system.
Amino acid metabolism measurements in glioma also show potential useful results. The high contrast achieved in images due to the low amino acid demand of normal brain has enabled Erikson et al. (1987) to show more accurately the growing edge of cerebral tumours using PET images of C"-1-Methionine (CMT). It may be that the metabolism of essential amino acids can give a signal related to protein synthesis rates in tumours, making these measurements a sensitive marker of the early effects of therapy at the cellular level. An example of the use of CMT is shown in Bergstrom et al. (1987) where the response of prolactinomas to bromocriptine is shown within hours of the start of treatment.
The effects of blood-brain-barrier permeability on drug access have been studied by Ott et al. (1990) using PET and Ga68-EDTA. This study has shown that there are rapid changes in permeability at the site of primary cerebral lymphomas during chemotherapy. It appears likely that local access of drugs to the tumour is radically impaired 4-5 weeks after treatment implying that drug treatment protocols for cerebral tumours require careful planning.
R.J. OTT Cellular proliferation
Another area of growing interest in the applications of PET to oncology is the possibility of measuring cell proliferation rates in situ using F'8-fluorodeoxyuridine (FUDR) or C"-thymidine (TDR). Wilson et al. (1990) have shown a strong correlation between FUDR (an RNA label) uptake in glioma and the histopathology of the tumour. In particular they show that the growing edge of the tumour is well defined by this agent. However the complex in vivo metabolism of this agent has made it difficult to establish whether the localisation mechanisms is RNA labelling or due to amino acid metabolites.
Two groups at Seattle, USA and Leuven, Belgium are investigating the use of TDR. The former have shown (Shields et al., 1990 ) that within 1 h of administration to the dog 40-80% of the TDR is incorporated into DNA. Both groups are presently working on methods of labelling TDR in the ring-2 position as reported by Vander Borght et al. (1990) to minimise the signal from metabolites. The images will then give a more accurate measure of DNA incorporation.
Anti-cancer drug kinetics
The radiolabelling of anti-cancer drugs will enable measurements of in vivo drug kinetics to be made using PET imaging. Dimitrakopoulou et al. (1990a,b) have imaged tracer dose of F'8-5FU given to patients with liver metastasis from colonic carcinoma. These data show a strong correlation between the initial uptake of the tracer in the metastases and the response to 5FU therapy. Yang et al. (1990) have recently labelled tamoxifen with F'8 and the group at ICR have labelled iodo-tamoxifen with 1124 allowing the possibility of pretherapy tracer studies leading to dosimetry. It is also possible of course to measure the uptake of radiolabelled drugs in normal tissues which will allow a more accurate prediction of toxicity to the kidneys, for instance, to therapy doses. With the growing importance of systemic drug therapy such methods of predicting drug uptake in individual patients are likely to become of increasing value in managing limited resources.
Receptor ligand imaging
The study of the role of PET receptor ligands in oncology is still in its infancy, but initial reports indicate some success in both localising tumours with appropriate ligands and in determining receptor density from images. Muhr et al. (1986) report the successful monitoring of the effects of bromocriptine treatment on pituitary tumours using C"-N-methylspiperone to visualise and quantify dopamine-D2 receptor binding. Similar results were also obtained with C"I-raclopride An obvious area of interest will be the use of positron emitter labelled monoclonal antibodies to add improved sensitivity and spatial resolution to the purported specificity of these agents to tumours. Bakir et al. (1990) report successful in vitro and laboratory based studies using I'24-labelled ICR12, and c-erbB2 proto-oncogene product antibody which may prove to be a useful prognostic tool in breast cancer. Wilson et al. (1990) have quantitated the uptake of the anti-EMA antibody HMFGI in both primary and locally recurrent breast tumours again using 1124 as the tracer label. They show that uptake in these tumours is generally only a little larger than that obtained with a non-specific control and found no correlation betw,en tumour uptake and blood flow as measured using O'5-water.
A final interesting result comes from Seattle (Koh et al., 1990 ) who have used the tracer F'8-fluoromisonidazole in an attempt to determine the hypoxic fraction in tumours. Preliminary studies in dog osteosarcomas have been extended to patients with tumours of the head and neck. Positive uptake of the tracer in excess of blood activity levels have been seen, but the relationship of this result to the binding to hypoxic cells has yet to be ascertained.
Conclusions
There are already some areas in which PET may have some direct clinical input into oncology. The differentiation between benign conditions such as radiation induced necrosis and tumour regrowth is of obvious importance in a wide range of tumour sites. Studies have shown that both F'8-FDG and amino acids are appropriate tracers here. Measurements of protein synthesis or cellular proliferation in vivo should provide important methods for determining those patients most likely to benefit from accelerated radiotherapy.
Similarily anti-cancer drug dopiihetry could well target expensive treatment to responding patients and save non-responders from the worst of the side effects.
Whilst PET is still an expensive technique there will be five centres in operation in the UK in the next 2 years and there should be further possibilities to expand on a broader front (Ott, 1987) by sharing radiopharmaceutical facilities on a regional basis. The unique, quantitative, functional information provided by PET makes it an exciting addition to the imaging tools available to the oncologist to help improve both diagnosis and therapy.
